Emmaus Life Sciences, Inc. announced that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari in the Kingdom of Bahrain. Endari is approved in the U.S., the United Arab Emirates, Israel, Kuwait, the State of Qatar and Bahrain to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.